Since the majority of TREM2 variants linked to Alzheimer’s disease (AD) are suggested to result in disease mechanisms through loss-of-function mechanisms, enhancing TREM2 expression—even in patients without any TREM2 mutations—has been proposed as an alternative therapeutic approach. This evidence concerns the gene TREM2 and early-onset autosomal dominant Alzheimer disease.